Abstract

Skype Talk: Contradiction of Precision Medicine Drugs

Stephen Naylor, Chairman & Chief Executive Officer, MaiHealth Inc & ReNeuroGen LLC

In 2015, ~29% of new drugs approved by the USA Federal Drug Administration were “Precision Medicine Drugs’. This fast emerging new type of therapeutic agent appears to be fraught with contradictions. We will discuss the major critical issues associated with Precision Medicine Drugs, including the time, cost, risk and complexity of bringing such entities to market.